AP-5346

N/A

Report date: 2022/03/23 14:31:01
NME

Base Information

Drug NameAP-5346
Drug Alias NameProLindacASK-H03AP-5346
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAlkylating agentsDNA inhibitors
TargetsDNA
Therapy Area/IndicationsHead and Neck NeoplasmsColorectal NeoplasmsBiliary Tract Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAbeona Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Cancer InstituteAbeona Therapeutics IncDong-A Pharmaceutical Co Ltd +[4] 
Active IndicationsN/A
Inactive IndicationsHead and Neck NeoplasmsColorectal NeoplasmsBiliary Tract Neoplasms

Other Information

ATC CodeN/A
Related LinksDrugBank